DNSK International, LLC.

Dhanapalan Nagarathnam, Ph. D., President & CEO

Dr. Dhanapalan Nagarathnam has over 35 years of experience in Medicinal Chemistry/Pharmaceutical research. This includes experience at Pharmasset (aquired by Gilead), NJ, Bayer HealthCare, West Haven, CT, and  Synaptic Pharmaceutical Corporation (currently Lundbeck), Paramus, NJ. His experiences include project management, medicinal chemistry, combinatorial chemistry, high-throughput synthesis, lead generation, lead optimization, process research, and production. Dr. Nagarathnam worked in many therapeutic areas including cancer, virology, diabetes, obesity, pain, and benign prostatic hyperplasia. He also managed internal and external collaboration projects with many biotechs and pharmas. Dr. Nagarathnam is an inventor/co-inventor of many clinical candidates and contributed to multiple discovery projects. Dr. Nagarathnam graduated from University of Madras, India with Ph.D. in Organic/Medicinal Chemistry and conducted postdoctoral research at University of California, Purdue University Cancer Center, and University of Illinois on several therapeutic areas. Overall, Nagarathnam is an inventor/author on over 100 patents/patent applications, peer-reviewed publications and conference presentations.

Dr. Nagarathnam also developed commercial scale processes for many APIs (Active Pharmaceutical Ingredients). We can also develop suitable DP (Drug Products) with the experience of Dr. Nagarathnam.

Representative Co-authored Publications

Kinase Inhibitors & Cancer:

JMC, 1991, 34, 798. JMC, 1991, 34, 2579.

BioOrg. MedChem. Lett, 1991, 1, 211.

VIROLOGY - HCV, ZIKA

236th National Meeting, MEDI-330 (2008).

JMC, 2010, 53(19), 7202.

BioOrg. MedChem. Lett. 2010, 20(24), 7376.

ACS MedChem. Lett. 2011, 292), 130.

GPCR Mediated Diseases

Nature, 1988, 396, 674.

JMC, 1998, 41, 5320, JMC. 1999, 42, 4804.,

JMC, 1999, 42, 4794, JMC. 1999, 42, 4778,  ,